Anti-HMGCR Myopathy in Remission: Whether a Statin Can Ever Return
A single patient in sustained remission from a statin-associated autoimmune myopathy, with a real cardiovascular indication for LDL-lowering. The disagreement is over whether this disease behaves like ordinary statin intolerance.
Walt H., 67, has run his own small orchard alone since his wife died several years ago, still climbing ladders most mornings during harvest season. Eighteen months ago, after nine uninterrupted years on the atorvastatin started the week of his myocardial infarction and drug-eluting stent placement, he developed profound proximal weakness and a creatine kinase above 8,000 — statin-associated anti-HMGCR-positive necrotizing autoimmune myopathy, confirmed on biopsy and antibody testing. High-dose steroids, IVIG, and then mycophenolate maintenance brought him into sustained remission: normal CK for six months, off steroids entirely, his anti-HMGCR titer trending down on serial testing.
His cardiology team, tracking an LDL that has climbed to 168 mg/dL on no lipid-lowering therapy for eighteen months, wants a statin restarted given his real secondary-prevention indication. What makes this different from an ordinary statin-intolerant patient is mechanism, not just history: statin exposure is thought to upregulate HMGCR expression on regenerating muscle fibers in genetically susceptible people, which can perpetuate the autoimmune process independent of whether the drug itself is still being taken — unlike typical statin myalgia, which reliably resolves once the drug stops and doesn't return unless the drug does. That distinction isn't theoretical, and the published evidence is a step stronger than a single anecdote: Yerolatsite and colleagues, reporting five patients with statin-associated anti-HMGCR myopathy in Rheumatology International in 2025, recorded relapse after statin rechallenge in two of them — while every patient given a PCSK9 inhibitor after myositis onset tolerated it, only one requiring any additional immunosuppression. Re-exposure in this specific, antibody-positive population is therefore a described trigger for relapse rather than a hypothetical risk to be managed with careful monitoring, in a disease that can become considerably harder to control the second time around — and the same small series is the reason the alternative route is not merely theoretical either.
At the joint rheumatology-cardiology visit, eighteen months clean
His LDL is 168 with a documented MI and stent, off any lipid-lowering therapy for a year and a half. Statins remain the best-evidenced LDL-lowering intervention we have, with the largest cardiovascular outcomes trial base of any drug class. I'd propose a cautious rechallenge — a hydrophilic statin, low dose, close CK monitoring.
His cardiovascular risk is real, and I'm not dismissing it. But anti-HMGCR disease isn't ordinary statin myalgia. The leading mechanistic explanation is that statin exposure upregulates HMGCR expression in regenerating muscle fibers in genetically susceptible patients — which can keep the autoimmune process going independent of whether the drug is still being taken. "Lower dose, closer monitoring" is the right answer for ordinary statin intolerance. It doesn't neutralize this risk the same way.
And this is documented, not inferred: in Yerolatsite's 2025 series of five statin-associated anti-HMGCR patients, two relapsed after rechallenge. Close CK monitoring catches a flare only after it's already started, in a disease that can become considerably harder to treat the second time.
I don't think we need to adjudicate how much risk is acceptable here, because there's a way to avoid the question. PCSK9 inhibitors like evolocumab lower LDL through a mechanism — promoting LDL-receptor recycling — that has no overlap with HMGCR at all, and FOURIER established their real cardiovascular-outcome benefit in a secondary-prevention population much like his.
Evolocumab typically achieves LDL reductions equal to or greater than what a statin would, and ezetimibe can be layered on for further lowering if needed. There's no remaining clinical reason to accept even a small, mechanistically grounded relapse risk when an alternative pathway reaches the same cardiovascular goal.
Agreed cleanly: start evolocumab, add ezetimibe if LDL remains above goal, continue mycophenolate maintenance with periodic anti-HMGCR titer and CK checks, and no statin of any kind goes back on his medication list.
The cardiologist's initial instinct toward a cautious rechallenge didn't survive the mechanistic argument once the case-report precedent was on the table — once a genuinely mechanism-independent alternative reaches the same LDL target, there was no remaining reason to accept even a small, well-described relapse risk.